Document Type : Original Article(s)
Authors
1
Assistant Professor, Department of Hematology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2
Nutritionist, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3
General Practitioner, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4
Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: ARG is a proto-oncogene and a member of a tyrosine kinase proteins family. It has great importance in many cancers, but there is no conclusive evidence on its role in DLBCL staging. The aim of this study was to evaluate importance of ARG, in this cancer's staging. Methods: Sixteen DLBCL and 4 reactive lymph node (as control group) samples, after staging using Ann Arbor staging system, were used in this study. Formaldehyde fixed paraffin embedded blocks were prepared from the samples. After the sectioning, all samples were hybridized with primary antibodies against ARG and GAPDH (as control house keep keeping gene). The slides were then washed and hybridized with fluorescently labeled secondary antibodies (ARG, green labeled and GAPDH, red). After capturing the pictures using CCD camera, the intensity of green and red colures was measured and the ratio between green/red, that demonstrate changes in ARG expression, were calculated. Findings: The mean ratio of green/red (ARG expression) was significantly different between reactive lymph node, stage I, II and III of DLBCL. ARG expression was different between all groups except for between stage III and VI of DLBCL. Conclusion: The observed changes in ARG expression is a potential biomarker for DLBCL staging. In addition specific inhibitors of ARG can be considered as new chemotherapy agents in the DLBCL treatment. Key words: Lymphoma, ARG, DLBCL
)